AskAt Inc. (AskAt), headquartered in Nagoya, Japan, today announced a license agreement with NewBay Medical Technology Co., Ltd. (NewBay), headquartered in Hangzhouwan New Zone, Ningbo, Zhejiang Province, People’s Republic of China (China), granting NewBay exclusive rights to develop, manufacture and commercialize AskAt’s EP4 Antagonist [AAT-008] in China in the area of Immuno-Oncology. Under the terms of the signed agreement, AskAt will receive upfront payments from NewBay and is eligible to receive Development and Commercial Milestone payments and Royalties on sales of products in China.
AAT-008 is a novel prostaglandin EP4 antagonist that has exhibited potent anti-tumor activity in animal models of lung, breast, colon, stomach, prostate, and liver cancers, and synergistic activity in combination with anti-PD-1 anti-body.
AskAt is a new kind of life sciences company, an open collaboration catalyst, with a team of highly dedicated and experienced professionals. AskAt accelerates innovation in small molecule R&D by designing and implementing highly optimized platforms, value-enhancing life cycle partnering opportunities, around its core intellectual property. AskAt’s R&D programs are focused on areas of critical, unmet patient needs, including cancer, Alzheimer’s Disease, pain, autoimmune disorders, and blindness caused by macular degeneration. For more information, please contact us at firstname.lastname@example.org.
NewBay is a VC-backed biotech company and is focusing to develop innovative medicine for China. The focused disease areas for NewBay are infectious diseases and oncology, both with high unmet medical needs.